CA3000405A1 - Methods for subtyping diffuse large b-cell lymphoma (dlbcl) - Google Patents

Methods for subtyping diffuse large b-cell lymphoma (dlbcl) Download PDF

Info

Publication number
CA3000405A1
CA3000405A1 CA3000405A CA3000405A CA3000405A1 CA 3000405 A1 CA3000405 A1 CA 3000405A1 CA 3000405 A CA3000405 A CA 3000405A CA 3000405 A CA3000405 A CA 3000405A CA 3000405 A1 CA3000405 A1 CA 3000405A1
Authority
CA
Canada
Prior art keywords
nucleic acid
sample
ptprc
pim1
rel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3000405A
Other languages
English (en)
French (fr)
Inventor
Bonnie LAFLEUR
Qian Liu
John W. Luecke
Patrick C. Roche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HTG Molecular Diagnostics Inc
Original Assignee
HTG Molecular Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HTG Molecular Diagnostics Inc filed Critical HTG Molecular Diagnostics Inc
Publication of CA3000405A1 publication Critical patent/CA3000405A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3000405A 2015-09-29 2016-09-29 Methods for subtyping diffuse large b-cell lymphoma (dlbcl) Pending CA3000405A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234491P 2015-09-29 2015-09-29
US62/234,491 2015-09-29
PCT/US2016/054501 WO2017059108A1 (en) 2015-09-29 2016-09-29 Methods for subtyping diffuse b-cell lymphoma (dlbcl)

Publications (1)

Publication Number Publication Date
CA3000405A1 true CA3000405A1 (en) 2017-04-06

Family

ID=57138148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3000405A Pending CA3000405A1 (en) 2015-09-29 2016-09-29 Methods for subtyping diffuse large b-cell lymphoma (dlbcl)

Country Status (9)

Country Link
US (1) US11384399B2 (enExample)
EP (1) EP3356554B1 (enExample)
JP (1) JP6836586B2 (enExample)
CN (1) CN108368554B (enExample)
AU (1) AU2016331058B2 (enExample)
BR (1) BR112018006393A2 (enExample)
CA (1) CA3000405A1 (enExample)
ES (1) ES2765709T3 (enExample)
WO (1) WO2017059108A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696250B2 (en) * 2016-11-09 2023-07-04 Intel Corporation UE and devices for detach handling
WO2018231589A1 (en) 2017-06-14 2018-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for determining lymphoma type
WO2019036632A1 (en) * 2017-08-18 2019-02-21 Health Research, Inc. COMPOSITIONS AND METHODS FOR DETECTION OF CD30 MRM ISOFORMS FOR USE IN DRUG SELECTION
JP7357921B2 (ja) * 2017-09-29 2023-10-10 国立大学法人九州大学 びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
CA3131874A1 (en) * 2019-03-28 2020-10-01 Philippe RUMINY Classification of b-cell non-hodgkin lymphomas
CN111621565B (zh) * 2020-05-07 2023-12-15 杭州可帮基因科技有限公司 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置
CN114469949A (zh) * 2020-10-27 2022-05-13 正大天晴药业集团股份有限公司 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物
CN117987359B (zh) * 2024-02-18 2024-08-30 中源协和生物细胞存储服务(天津)有限公司 用于从生物材料中分离细胞外囊泡的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ES2155822T3 (es) 1990-12-06 2001-06-01 Affymetrix Inc Compuestos y su utilizacion en una estrategia de sintesis binaria.
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO1995030774A1 (en) 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5866330A (en) 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5736330A (en) 1995-10-11 1998-04-07 Luminex Corporation Method and compositions for flow cytometric determination of DNA sequences
US6449562B1 (en) 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
GB9624586D0 (en) 1996-11-27 1997-01-15 British Nuclear Fuels Plc Improvements in and relating to coils
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6238869B1 (en) 1997-12-19 2001-05-29 High Throughput Genomics, Inc. High throughput assay system
US6458533B1 (en) 1997-12-19 2002-10-01 High Throughput Genomics, Inc. High throughput assay system for monitoring ESTs
US20030096232A1 (en) 1997-12-19 2003-05-22 Kris Richard M. High throughput assay system
US6232066B1 (en) 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
AU2375600A (en) 1998-12-22 2000-07-12 Stephen Felder High throughput assay system using mass spectrometry
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
DE102005030336A1 (de) 2005-06-29 2007-01-04 Peri Gmbh Schienengeführtes Klettersystem
ATE525482T1 (de) 2005-12-23 2011-10-15 Nanostring Technologies Inc Nanoreporter und verfahren zu deren herstellung und verwendung
US20080268451A1 (en) 2007-03-30 2008-10-30 Bruce Seligmann Measurement of an insoluble analyte in a sample
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
WO2010117817A2 (en) * 2009-03-30 2010-10-14 Life Technologies Corporation Methods for generating target specific probes for solution based capture
AU2011224166B2 (en) 2010-03-12 2014-08-21 Celgene Corporation Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
AU2012251027B2 (en) 2011-05-04 2015-03-26 Htg Molecular Diagnostics, Inc. Quantitative nuclease protection Assay (qNPA) and sequencing (qNPS) improvements
EP3066215B1 (en) 2013-11-06 2019-04-24 The United States of America, represented by the Secretary, Department of Health and Human Services Method for subtyping lymphoma types by means of expression profiling

Also Published As

Publication number Publication date
AU2016331058B2 (en) 2022-04-07
CN108368554A (zh) 2018-08-03
US20180340231A1 (en) 2018-11-29
JP2018536387A (ja) 2018-12-13
EP3356554B1 (en) 2019-10-30
US11384399B2 (en) 2022-07-12
WO2017059108A1 (en) 2017-04-06
ES2765709T3 (es) 2020-06-10
BR112018006393A2 (pt) 2018-10-09
EP3356554A1 (en) 2018-08-08
CN108368554B (zh) 2022-09-09
AU2016331058A1 (en) 2018-04-26
JP6836586B2 (ja) 2021-03-03

Similar Documents

Publication Publication Date Title
AU2016331058B2 (en) Methods for subtyping diffuse large b-cell lymphoma (dlbcl)
EP3737774B1 (en) Method for analyzing nucleic acid
EP3583214B1 (en) Methods and compositions for identifying or quantifying targets in a biological sample
EP2864500B1 (en) Molecular malignancy in melanocytic lesions
US20200277600A1 (en) Multi-effector crispr based diagnostic systems
JP2021508460A (ja) Ｃｒｉｓｐｒエフェクター系に基づくマルチプレックス診断
Coudry et al. Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue
KR20190104030A (ko) Crispr 이펙터 시스템 기반 진단
US20130178372A1 (en) Methods And Computer Systems For Identifying Target-Specific Sequences For Use In Nanoreporters
JP2018524993A (ja) 染色体異常を検出するための核酸及び方法
AU2016297510A1 (en) Methods of amplifying nucleic acid sequences
US12618101B2 (en) Sherlock assays for tick-borne diseases
WO2014149629A1 (en) Subtyping lung cancers
CA2859663A1 (en) Identification of multigene biomarkers
EP4172357B1 (en) Methods and compositions for analyzing nucleic acid
JP2023109998A (ja) マイクロサテライト不安定性の検出
WO2010021696A1 (en) Methods and compositions for determining a graft tolerant phenotype in a subject
Joseph et al. Molecular Techniques/Molecular Diagnostics for Surgical Pathologists: An Overview
WO2017087735A1 (en) Method for treating crohn's disease
US12624475B1 (en) Capturing genetic targets using a hybridization approach
JP2006223303A (ja) 微量胃癌細胞の検出法
Yang et al. The Technologies: Comparisons on Efficiency, Reliability, and Costs
EP4584373A1 (en) Methods and compositions for analyzing nucleic acid
EP4544040A1 (en) Methods for the molecular subtyping of tumors from archival tissue
Dunbar et al. Bead array technologies for genetic disease screening and microbial detection

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210922

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20240828

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20240828

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20241031

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260311

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: FINAL FEE PAID AND APPLICATION REINSTATED

Effective date: 20260330

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260330

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260330